OncoZenge's lead product is BupiZenge, an oral lozenge formulation of the anaesthetic bupivacaine. The dru's lead indication is oral mucositis, which affects patients receiving cancer treatment. BupiZenge has demonstrated significantly better pain relief compared to standard of care in this indication in a Phase II trial.